The Opportunity

eTect has developed an innovative solution to collecting vital clinical trial information sought by
the healthcare industry for many years: adherence.

Billions of dollars are spent each year developing new drugs. Reports from the Tufts Center for
the Study of Drug Development place the average cost to develop a single new drug at $802
million, of which the clinical trial phase may consume up to half. Clinical trials are the fundamental
evaluation of safety and efficacy of a new drug. The average cost per participant in a clinical trial
in 2008 was $7931. Estimates derived from clinicaltrials.gov and other sources indicate more
than 2 million people participated in clinical drug trials in 2009.

How many participants in clinical trials took their medicine as prescribed? No one knows.

In addition to clinical trials, poor medication adherence has a significant negative impact on
healthcare costs. The New England Journal of Medicine finds that, "of all medication-related
hospital admissions in the United States, 33 to 69 percent are due to poor medication adherence,
with a resultant cost of approximately $100 billion a year."

eTect Solution

eTect is a development stage company creating ID-Cap, an innovative solution that uses novel
wireless and materials technology and the mobile internet infrastructure to provide real-time
verification of medication adherence. The patented ID-Cap system consists of three major
elements: 1) biocompatible transponder tags affixed to the medication; 2) a reader worn by the
patient, and; 3) a user interface application residing on a mobile phone.

Cost of Clinical Trials

> 2,000,000 participants/year

average cost - $7931/person

> $15 Billion per year

Case in Point

Experimenting with a system similar to ID-Cap, Novartis documented medication
adherence improvement from 30% to 80% in six months.

- as reported in Financial
  Times, Sept. 21, 2009
Improved Adherence – Improved Outcomes

As stated by former Surgeon General C. Everett Koop, “Drugs don’t work in patients who don’t take them.” A fundamental requirement of improving adherence is being able to measure it. ID-Cap enables definitive measurement of medication adherence. In clinical trials, adherence data improves the quality of information on safety and efficacy of new drugs. Multiple studies have shown that improved adherence can lead to more effective, less expensive clinical trials.

eTect will enable the trial sponsor and/or administrator to deploy ID-Cap, collect adherence data and place it in an adherence information database. The Company intends to offer a turnkey adherence information service where eTect will contract with the trial sponsor or administrator to provide real-time adherence information. The Company also intends to offer technology and components such as ID-Cap tags and readers for sale to trial sponsors and administrators to integrate the technology into their own clinical studies.

“I love the idea. My division is sponsoring many trials for addiction and HIV where we need to follow how adherent people are to the protocol. Current technologies do not tell us if the patients actually took their pills. This technology would be very, very important for clinical trials.”

- Dr. Jag H. Khalsa, Ph.D., National Institute on Drug Abuse, National Institutes of Health

Current Status

The Company has completed development of and conducted live human demonstrations with a proof of concept ingestible pill. This pill, made from off-the-shelf components and encapsulated in epoxy, demonstrates and validates the ID-Cap in vivo communications and gastrointestinal (GI) sensor.

The eTect engineering team has achieved a number of important milestones in the development of the microchip, the GI sensor, and the ID-Cap tag including manufacturing, application to the target medication, and analyses of stability, dissolution properties, and biocompatibility. The Company has also determined what it believes to be a clear regulatory pathway for use of ID-Cap in clinical trials of new drugs.

Intellectual Property

The Company has received notice of allowance of a significant portion of the claims in patent application (11/458,815) for a Medication Compliance System and we continue to file additional applications to improve our intellectual property portfolio. The Company has executed exclusive option agreements with the University of Florida (UF) for the eBurst in vivo communication method patent application and the biocompatible nanoparticle ink patent application and is currently negotiating terms with UF for exclusive rights to these patent applications.

Contact Information

Eric Buffkin, President  
eric@etectbio.com  
+1.352.262.8947 cell  
+1.352.367.8328 x102 office

Neil Euliano, CEO  
neil@etectbio.com  
+1.352.514.7459 cell  
+1.352.367.8328 x107 office

eTect llc  
4817 SW 34th St, Suite 4  
Gainesville, FL 32608  
www.etectbio.com